Edwards Lifesciences' (EW) robust potential in the TAVR (Transcatheter Aortic Valve Replacement) business is poised to help it grow in the upcoming quarters. The company's decision to sell the Critical Care arm supports its goal of developing a comprehensive structural heart portfolio. Also, sound solvency instills optimism. However, rising costs and adverse currency impacts remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has dropped 11.3% against the 9.3% rise of the indu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (State or other j ...

The Company has prepared and mailed its management information circular (the "Circular") and related proxy materials (collectively, the "Meeting Materials") to its shareholders ("Shareholders") in connection with the special meeting of Shareholders to be held at 10:00 a.m. (Vancouver time) on August 16, 2024 (the "Meeting"). The Meeting Materials have been mailed to Shareholders of record as of July 10, 2024 (the "Record Date"). At the Meeting, Shareholders will be asked to consider, and if deemed advisable ...

Have you assessed how the international operations of Edwards Lifesciences (EW) performed in the quarter ended June 2024? For this medical device maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. Fo ...

Edwards Lifesciences (NYSE:EW) released its Q2 FY24 result on July 24th, with a disappointing guidance cut for its transcatheter aortic valve replacement (TAVR) revenue growth. I gave a 'Strong Buy' rating in my previous coverage published in February 2024, pointing out their EVOQUE Growth Opportunities. While TAVR growth is slowing down, I remain positive about the long-term growth potential. The sell-off of the stock creates a good entry point for buying. I reiterate my 'Strong Buy' with a fair value of $ ...

The S&P 500 slipped 0.5% on Thursday, July 25, as tech stocks faltered for a second straight day even as data showed an uptick in GDP growth. Edwards Lifesciences shares plunged after the medtech firm cut its sales forecast for a critical heart device. Shares of ServiceNow moved higher following a strong earnings report buoyed by subscription revenue growth. Although indications of persistent economic strength temporarily took the spotlight on Thursday, boosting stocks in intraday trading, the concerns abou ...

Edwards Lifesciences (EW) shares swooned Thursday, dropping after the company damped expectations for heart valve replacement sales growth on Wednesday. Shares of Edwards plunged 31% to finish at $59.76 Thursday, leaving them down about 22% this year. The stock was the day's worst performer in the S&P 500. tips@investopedia.com Edwards Lifesciences cut sales-growth estimates for its biggest source of revenue, a heart valve replacement treatment. The heart disease and critical care monitoring company also mi ...

Quest Diagnostics, carrying a Zacks Rank #2, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion exceeded the Zacks Consensus Estimate by 0.5%. DGX's historical five-year earnings growth rate of 7.4% compares favorably with the industry's 4.2%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 3.31%. Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 7 ...

Edwards Lifesciences (NYSE:EW) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents. This just beats out Wall Street's estimate of 69 cents per share. It's also better than the 66 cents per share reported in the same period of the year prior. However, the company's revenue of $1.63 billion failed to impress investors. That comes in below analysts' estimate of $1.65 billion for the perio ...

Edwards Lifesciences Corporation (NYSE:EW) Q2 2024 Earnings Conference Call July 24, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President of TAVR and Surgical Structural Heart Daveen Chopra - Global Leader of TMTT Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Travis Steed - Bank of America Matthew Taylor - Jefferies Vijay Kumar - Everc ...